Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Claritin label change

This article was originally published in The Tan Sheet

Executive Summary

FDA approves Schering-Plough's request to add the descriptor "Indoor & Outdoor Allergies" to the principal display panel of 10- and 30-count carton labels of Claritin Liqui-Gels (loratadine 10 mg), according to an April 6 letter. The change could extend the medicine's benefits beyond seasonal allergies. FDA approved a similar change to Claritin packaging in 2008 (1"The Tan Sheet" Jan. 28, 2008, In Brief)

You may also be interested in...

FDA approves new Claritin label

FDA will allow Schering-Plough to communicate on its product label that Claritin relieves both indoor and outdoor allergies, potentially extending the OTC non-drowsy allergy medicine's benefits beyond seasonal allergy treatment. Previously, labels could only state that Claritin relieves outdoor allergies, S-P says Jan. 22...

EU’s SCCS Finds Endocrine-Disrupting Evidence Inconclusive In UV Filter Reassessments

While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.

US FDA Urges COVID-19 Transmission Risk Mitigation In Cell And Gene Therapy Manufacturing

The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts